1. Home
  2. XPOF vs IKT Comparison

XPOF vs IKT Comparison

Compare XPOF & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xponential Fitness Inc.

XPOF

Xponential Fitness Inc.

HOLD

Current Price

$6.79

Market Cap

273.4M

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$1.82

Market Cap

220.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XPOF
IKT
Founded
2017
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Services-Misc. Amusement & Recreation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
273.4M
220.5M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
XPOF
IKT
Price
$6.79
$1.82
Analyst Decision
Hold
Strong Buy
Analyst Count
6
5
Target Price
$8.13
$5.00
AVG Volume (30 Days)
548.2K
583.1K
Earning Date
05-07-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
35.24
57.76
EPS
N/A
N/A
Revenue
$11,092,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$6.63
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.83
$1.33
52 Week High
$11.14
$2.26

Technical Indicators

Market Signals
Indicator
XPOF
IKT
Relative Strength Index (RSI) 65.44 61.33
Support Level $6.64 $1.63
Resistance Level $7.08 $1.91
Average True Range (ATR) 0.34 0.08
MACD 0.16 0.02
Stochastic Oscillator 88.33 100.00

Price Performance

Historical Comparison
XPOF
IKT

About XPOF Xponential Fitness Inc.

Xponential Fitness Inc is a franchisor of boutique health and wellness brands. It operates a diversified platform of five brands spanning across verticals, including Pilates, barre, stretching, functional training, and yoga. Through its subsidiary, it offers an energetic, accessible, and personalized workout experience led by qualified instructors in studio locations throughout North America and internationally. The company's portfolio of brands includes Club Pilates; StretchLab; YogaSix; Pure Barre; and BFT. It operates in a single segment of the franchise business of its health and wellness brands.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: